Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

92.45 -0.48 (-0.52%)

Streaming Delayed Price Updated: 9:31 AM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

FDA Approves Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA® (pembrolizumab)

September 19, 2025

From Merck & Co., Inc.

Via Business Wire

Merck Scores Positive Feedback From EU Agency Regarding Blockbuster Cancer Drug ↗

September 19, 2025

Merck received positive Keytruda notes from CHMP regarding its breakthrough cancer treatment with final decisions expected in late 2025.

Via Benzinga

Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes

September 19, 2025

Eli Lilly and Company (NYSE: LLY) is making significant waves in the oncology landscape with a series of major announcements concerning two of its innovative cancer therapies: Olomorasib and Jaypirca...

Via MarketMinute

Merck Says EMA Committee Adopted Two Positive Opinions For Expanding Use Of Cancer Drug Keytruda ↗

September 19, 2025

Via Stocktwits

SLB, Apple, Nvidia, Merck, Gilead Sciences: What Sparked Heavy After-Hours Trading In These 5 Stocks? ↗

September 11, 2025

Via Stocktwits

Decoding Merck & Co's Options Activity: What's the Big Picture? ↗

September 19, 2025

Via Benzinga

Merck Receives Positive EU CHMP Opinion for ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) in Infants During Their First RSV Season

September 19, 2025

From Merck & Co., Inc.

Via Business Wire

Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer

September 19, 2025

From Merck & Co., Inc.

Via Business Wire

Merck Reportedly Scraps Research Centre In UK: Retail Sees Stock Rallying To $97.50 ↗

September 10, 2025

Via Stocktwits

Elizabeth Warren Says Measles Can Hit Record Highs, Slams RFK Jr.'s CDC Panel For Delaying Vaccine: 'How Does That Keep Our Kids Safe?' ↗

September 18, 2025

Sen. Elizabeth Warren (D-Mass.) on Thursday criticized the Centers for Disease Control and Prevention's vaccine advisory panel following its controversial vote to delay the combined measles, mumps,...

Via Benzinga

Advancing Cancer Research Brings New Hope for Patients Worldwide

September 17, 2025

Via Investor Brand Network

Topics Artificial Intelligence Intellectual Property

Advancing Cancer Research Brings New Hope for Patients Worldwide

September 17, 2025

EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOVA),(NYSE:MRK),(NASDAQ:AZN),(NYSE:BMY) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Artificial Intelligence Intellectual Property

Robert Kennedy Jr. Packs CDC Panel With Vaccine Skeptics Ahead of Key Vote On COVID-19 Shots ↗

September 15, 2025

Health and Human Services Secretary Robert F. Kennedy Jr. has added five new members to the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices, just days...

Via Benzinga

The Weight of Progress: A New Era Dawns for Anti-Obesity Drugs, Reshaping Markets and Health

September 15, 2025

The global anti-obesity drug market is experiencing an unprecedented surge, driven by groundbreaking advancements in pharmacotherapy, particularly the advent of highly effective GLP-1 receptor...

Via MarketMinute

Merck & Co. Inc. (NYSE:MRK): A Prime Value Stock with Strong Profitability and Sound Finances ↗

September 15, 2025

Discover Merck & Co. (MRK), a top value stock with strong profitability, sound financial health, and an attractive valuation. A prime pick for value investors.

Via Chartmill

Raludotatug Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treated with Bevacizumab

September 15, 2025

From Daiichi Sankyo

Via Business Wire

2 Healthcare Dividend Stocks to Buy and Hold ↗

September 14, 2025

These drugmakers have competitive yields and have increased their dividends at a good clip.

Via The Motley Fool

Topics Intellectual Property

Merck & Co. Inc. (NYSE:MRK) Excels in Caviar Cruise Quality Stock Screen ↗

September 13, 2025

Discover Merck & Co. (MRK), a top-tier stock excelling in profitability, high ROIC, strong cash flow, and a robust balance sheet for long-term quality investing.

Via Chartmill

Merck's Exit Highlights UK Risks Losing Pharma Investment Amid Rising Costs ↗

September 12, 2025

Pharmaceutical companies are pulling investment from the UK as NHS drug spending falls and pricing disputes worsen.

Via Benzinga

Merck Advances Childhood Pneumococcal Care With Promising Vaccine Data ↗

September 11, 2025

Merck's Capvaxive vaccine showed strong immune responses and a comparable safety profile to PPSV23 in high-risk children during the Phase 3 STRIDE-13 trial.

Via Benzinga

CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Children and Adolescents at Increased Risk of Pneumococcal Disease

September 11, 2025

From Merck & Co., Inc.

Via Business Wire

Summit Therapeutics Crashes After Failing To Deliver Another Merck-Walloping Punch ↗

September 08, 2025

Summit Therapeutics stock crashed Monday after the company's drug failed to meet the bar for overall survival in lung cancer.

Via Investor's Business Daily

1 Profitable Stock to Own for Decades and 2 We Turn Down

September 08, 2025

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my...

Via StockStory

Topics Economy

Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences ↗

September 08, 2025

Summit's ivonescimab showed improved survival trends in NSCLC patients with favorable safety, though some results missed statistical significance thresholds.

Via Benzinga

Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial

September 07, 2025

From Daiichi Sankyo

Via Business Wire

Robert F. Kennedy Took Fire From Both Republicans And Democrats Over Vaccine Overhauls: GOP Senators Defend Trump's Operation Warp Speed ↗

September 05, 2025

Secretary for Health and Human Services, Robert F. Kennedy Jr., faced bipartisan backlash during a combative Senate hearing on Thursday, as both Republicans and Democrats criticized his controversial...

Via Benzinga

Topics Government

FDA Breakthrough Status Awarded To Lilly-Merck Combo Drug For Advanced Non-Small Cell Lung Cancer ↗

September 04, 2025

Eli Lilly's olomorasib with Merck's Keytruda receives FDA Breakthrough Therapy status for KRAS G12c lung cancer, supported by trial results.

Via Benzinga

3 Things You Need to Know if You Buy Pfizer Today ↗

September 04, 2025

Pfizer has a lofty 6.9% dividend yield, but is it the only or best choice for investors interested in the pharma space?

Via The Motley Fool

Topics Intellectual Property

Robert F. Kennedy Jr.'s Vaccine Shake-Up Sparks Coast-To-Coast Divide: West Coast Creates Health Alliance, Florida Rolls Back Requirements ↗

September 04, 2025

California, Oregon and Washington form regional vaccine alliance to counter federal guidance under Robert F. Kennedy Jr. as Florida eliminates state mandates.

Via Benzinga

Florida Chooses 'Medical Freedom' As State Plans To End Vaccine Mandates, Even For Schools: Experts Warn Of 'Major Disaster' ↗

September 04, 2025

Florida plans to end all statewide vaccine mandates, even those required for school attendance, framing the move as a defense of individual liberties, which has since received pushback from public...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Merck & Co (NY:MRK)

All News about Merck & Co

Starting at $3.75/week.

Subscribe Today